Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baobei Zhike Oral Liquid is a Traditional Chinese Medicine (TCM) formulation developed by the Gansu Yasheng Academy of Sciences and manufactured by Gansu Yasheng Pharmaceutical. It is primarily indicated for the treatment of respiratory conditions, including acute tracheobronchitis and acute exacerbations of chronic bronchitis. The oral solution is composed of several herbal extracts, including *Ephedra*, *Morus alba* (mulberry bark), *Descurainia sophia* (tansy mustard seed), and *Armeniaca sibirica* (bitter apricot seed). Its therapeutic effects are attributed to the synergistic action of its components, which provide bronchodilation (primarily via ephedrine's agonism of beta-2 adrenergic receptors), antitussive activity, and expectorant properties. While the name 'Baobei' (meaning 'Baby') suggests a pediatric focus, the formulation is also utilized for adult bronchial conditions characterized by cough, excessive phlegm, and shortness of breath.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baobei Zhike Oral Liquid.